BBLG Stock Overview
A medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bone Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.26 |
| 52 Week High | US$10.56 |
| 52 Week Low | US$0.80 |
| Beta | 0.74 |
| 11 Month Change | -27.17% |
| 3 Month Change | -11.27% |
| 1 Year Change | -61.86% |
| 33 Year Change | -99.86% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| BBLG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | -61.9% | 18.8% | 32.3% |
Return vs Industry: BBLG underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: BBLG underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| BBLG volatility | |
|---|---|
| BBLG Average Weekly Movement | 43.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BBLG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BBLG's weekly volatility has increased from 29% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2 | Jeff Frelick | www.bonebiologics.com |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Bone Biologics Corporation Fundamentals Summary
| BBLG fundamental statistics | |
|---|---|
| Market cap | US$3.20m |
| Earnings (TTM) | -US$7.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs BBLG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBLG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.35m |
| Earnings | -US$7.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BBLG perform over the long term?
See historical performance and comparison